Literature DB >> 33461313

Effect of Obstructive Sleep Apnea and Positive Airway Pressure Therapy on Cardiac Remodeling as Assessed by Cardiac Biomarker and Magnetic Resonance Imaging in Nonobese and Obese Adults.

Liyue Xu1,2, Brendan T Keenan2, David Maislin2, Thorarinn Gislason3,4, Bryndís Benediktsdóttir3,4, Sigrun Gudmundsdóttir3, Marianna Gardarsdottir5, Bethany Staley2, Frances M Pack2, Xiaofeng Guo2, Yuan Feng6, Jugal Chahwala7, Pritika Manaktala7, Anila Hussein7, Maheshwara Reddy-Koppula7, Zeba Hashmath7, Jonathan Lee7, Raymond R Townsend8, Richard J Schwab2, Allan I Pack2, Samuel T Kuna2,9, Julio A Chirinos7.   

Abstract

It is unknown whether obesity modifies the effect of obstructive sleep apnea (OSA) and positive airway pressure (PAP) therapy on cardiac remodeling and NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels. We compared NT-proBNP and cardiac magnetic resonance imaging in adults without OSA (n=56) and nonobese (n=73; body mass index <30 kg/m2) and obese (n=136; body mass index ≥30 kg/m2) adults with OSA. We also investigated these traits in nonobese (n=45) and obese (n=78) participants with OSA adherent to 4 months of PAP treatment. At baseline, left ventricular mass to end-diastolic volume ratio, a measure of left ventricular concentricity, was greater in both nonobese and obese participants with OSA compared with those without OSA. Participants with OSA and obesity exhibited reduced phasic right atrial function. No significant differences in baseline NT-proBNP were observed across groups. The effect of PAP treatment on NT-proBNP and left atrial volume index was significantly modified by obesity. In nonobese participants, PAP therapy was associated with a decrease in NT-proBNP (P<0.0001) without a change in left atrial volume index, whereas in obese participants, PAP was associated with an increase in left atrial volume index (P=0.006) without a change in NT-proBNP. OSA was associated with left ventricular concentric remodeling independent of obesity and right atrial dysfunction in participants who were obese. PAP treatment was associated with reduced NT-proBNP in nonobese participants with OSA, but left atrial enlargement in obese participants with OSA, suggesting that PAP-induced reduction in BNP release (which is known to occur during obstructive apnea episodes) may lead to volume retention in obese participants with OSA. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01578031.

Entities:  

Keywords:  magnetic resonance imaging; natriuretic peptide, brain; obesity; sleep apnea, obstructive

Mesh:

Substances:

Year:  2021        PMID: 33461313      PMCID: PMC7878363          DOI: 10.1161/HYPERTENSIONAHA.120.15882

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  48 in total

Review 1.  The paradox of low BNP levels in obesity.

Authors:  Aldo Clerico; Alberto Giannoni; Simona Vittorini; Michele Emdin
Journal:  Heart Fail Rev       Date:  2012-01       Impact factor: 4.214

2.  Obstructive sleep apnea and plasma natriuretic peptide levels in a community-based sample.

Authors:  Anjali A Patwardhan; Martin G Larson; Daniel Levy; Emelia J Benjamin; Eric P Leip; Michelle J Keyes; Thomas J Wang; Daniel J Gottlieb; Ramachandran S Vasan
Journal:  Sleep       Date:  2006-10       Impact factor: 5.849

Review 3.  Practice parameters for the indications for polysomnography and related procedures: an update for 2005.

Authors:  Clete A Kushida; Michael R Littner; Timothy Morgenthaler; Cathy A Alessi; Dennis Bailey; Jack Coleman; Leah Friedman; Max Hirshkowitz; Sheldon Kapen; Milton Kramer; Teofilo Lee-Chiong; Daniel L Loube; Judith Owens; Jeffrey P Pancer; Merrill Wise
Journal:  Sleep       Date:  2005-04       Impact factor: 5.849

4.  Late Systolic Myocardial Loading Is Associated With Left Atrial Dysfunction in Hypertension.

Authors:  Julio A Chirinos; Timothy S Phan; Amer A Syed; Zeba Hashmath; Harry G Oldland; Maheswara R Koppula; Ali Tariq; Khuzaima Javaid; Rachana Miller; Swapna Varakantam; Anjaneyulu Dunde; Vadde Neetha; Scott R Akers
Journal:  Circ Cardiovasc Imaging       Date:  2017-06       Impact factor: 7.792

5.  Left ventricular systolic and diastolic function in obstructive sleep apnea: impact of continuous positive airway pressure therapy.

Authors:  Mehmood Butt; Girish Dwivedi; Alena Shantsila; Omer A Khair; Gregory Y H Lip
Journal:  Circ Heart Fail       Date:  2012-03-13       Impact factor: 8.790

6.  B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures.

Authors:  Jennifer A Taylor; Robert H Christenson; Krishnamurti Rao; Melinda Jorge; Stephen S Gottlieb
Journal:  Am Heart J       Date:  2006-12       Impact factor: 4.749

Review 7.  Mechanisms of cardiac dysfunction in obstructive sleep apnea.

Authors:  Jean-Philippe Baguet; Gilles Barone-Rochette; Renaud Tamisier; Patrick Levy; Jean-Louis Pépin
Journal:  Nat Rev Cardiol       Date:  2012-09-25       Impact factor: 32.419

8.  Impact of CPAP treatment on cardiac biomarkers and pro-BNP in obstructive sleep apnea syndrome.

Authors:  Nilüfer Cifçi; Meral Uyar; Osman Elbek; Hüseyin Süyür; Erhan Ekinci
Journal:  Sleep Breath       Date:  2009-10-08       Impact factor: 2.816

9.  Cardiac hypertrophy in obstructive sleep apnea syndrome.

Authors:  A Noda; T Okada; F Yasuma; N Nakashima; M Yokota
Journal:  Chest       Date:  1995-06       Impact factor: 9.410

10.  Effect of sleep apnea and continuous positive airway pressure on cardiac structure and recurrence of atrial fibrillation.

Authors:  Tomas G Neilan; Hoshang Farhad; John A Dodson; Ravi V Shah; Siddique A Abbasi; Jessie P Bakker; Gregory F Michaud; Rob van der Geest; Ron Blankstein; Michael Steigner; Roy M John; Michael Jerosch-Herold; Atul Malhotra; Raymond Y Kwong
Journal:  J Am Heart Assoc       Date:  2013-11-25       Impact factor: 5.501

View more
  1 in total

1.  Adverse Thoracic Aortic Remodeling in Obstructive Sleep Apnea.

Authors:  Mahesh K Vidula; Julio A Chirinos
Journal:  Am J Hypertens       Date:  2022-06-16       Impact factor: 3.080

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.